Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site1

CTL directed against the Moloney murine leukemia virus (MuLV) epitope SSWDFITV recognize Moloney MuLV-induced tumor cells, but do not recognize cells transformed by the closely related Friend MuLV. The potential Friend MuLV epitope has strong sequence homology with Moloney MuLV and only differs in one amino acid within the CTL epitope and one amino acid just outside the epitope. We now show that failure to recognize Friend MuLV-transformed tumor cells is based on a defect in proteasome-mediated processing of the Friend epitope which is due to a single amino acid substitution (N→D) immediately flanking the C-terminal anchor residue of the epitope. Proteasome-mediated digestion analysis of a synthetic 26-mer peptide derived from the Friend sequence shows that cleavage takes place predominantly C-terminal of D, instead of V as is the case for the Moloney MuLV sequence. Therefore, the C terminus of the epitope is not properly generated. Epitope-containing peptide fragments extended with an additional C-terminal D are not efficiently translocated by TAP and do not show significant binding affinity to MHC class I-Kb molecules. Thus, a potential CTL epitope present in the Friend virus sequence is not properly processed and presented because of a natural flanking aspartic acid that obliterates the correct C-terminal cleavage site. This constitutes a novel way to subvert proteasome-mediated generation of proper antigenic peptide fragments.

[1]  U. Koszinowski,et al.  Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein , 1991, Cell.

[2]  L. Eisenlohr,et al.  Regulation of class I-restricted epitope processing by local or distal flanking sequence. , 1997, Journal of immunology.

[3]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[4]  J. Yewdell,et al.  Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes , 1992, The Journal of experimental medicine.

[5]  A. Goldberg,et al.  Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. , 1993, Nature.

[6]  L. Kaer,et al.  Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. , 1998 .

[7]  Stefan Imreh,et al.  Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1 , 1995, Nature.

[8]  P. Cresswell,et al.  How selective is the transporter associated with antigen processing? , 1996, Immunity.

[9]  H. Ploegh,et al.  Generation, translocation, and presentation of MHC class I-restricted peptides. , 1995, Annual review of biochemistry.

[10]  A. Goldberg,et al.  Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Neefjes,et al.  Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation. , 1997, Journal of immunology.

[12]  A. Goldberg,et al.  Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[14]  A. Rosato,et al.  Dissecting the Immune Response to Moloney Murine Sarcoma/Leukemia Virus-Induced Tumors by Means of a DNA Vaccination Approach , 1999, Journal of Virology.

[15]  R F Standaert,et al.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.

[16]  R. Offringa,et al.  An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. , 1995, Journal of immunology.

[17]  P. Kloetzel,et al.  The Interferon-γ-inducible 11 S Regulator (PA28) and the LMP2/LMP7 Subunits Govern the Peptide Production by the 20 S Proteasome in Vitro(*) , 1995, The Journal of Biological Chemistry.

[18]  A. Goldberg,et al.  Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.

[19]  P. Paz,et al.  Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER. , 1999, Immunity.

[20]  C. Rice,et al.  CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope , 1992, The Journal of experimental medicine.

[21]  H. Rammensee,et al.  The making of the dominant MHC class I ligand SYFPEITHI , 1998, European journal of immunology.

[22]  C. Melief,et al.  Cytotoxic T cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H‐2 requirements , 1981, European journal of immunology.

[23]  P M Kloetzel,et al.  A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. , 1996, Immunity.

[24]  N. Shastri,et al.  Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. , 1995, Journal of immunology.

[25]  Clive A. Slaughter,et al.  Proteolytic Processing of Ovalbumin and β-galactosidase by the Proteasome to Yield Antigenic Peptides , 1994 .

[26]  A. Goldberg,et al.  Interferon-γ Can Stimulate Post-proteasomal Trimming of the N Terminus of an Antigenic Peptide by Inducing Leucine Aminopeptidase* , 1998, The Journal of Biological Chemistry.

[27]  P. Kloetzel,et al.  The cleavage preference of the proteasome governs the yield of antigenic peptides , 1995, The Journal of experimental medicine.

[28]  M. Feltkamp,et al.  Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. , 1994, Molecular immunology.

[29]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[30]  R. Offringa,et al.  Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. , 1998, Cancer research.

[31]  M. Ressing,et al.  Identification of an H-2 Kb-presented Moloney murine leukemia virus cytotoxic T-lymphocyte epitope that displays enhanced recognition in H-2 Db mutant bm13 mice , 1994, Journal of virology.

[32]  H. Ploegh.  Viral strategies of immune evasion. , 1998, Science.

[33]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.

[34]  W Keilholz,et al.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Neefjes,et al.  Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling , 1994, The Journal of experimental medicine.

[36]  M. Lotze,et al.  Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[37]  L. Kaer,et al.  Immunoproteasome Assembly : Cooperative Incorporation of Interferon g ( IFN-g ) – inducible Subunits , 1997 .

[38]  W. Kast,et al.  Differential effect of transporter Tap 2 gene introduction into RMA‐S cells on viral antigen processing , 1993, European journal of immunology.

[39]  H. Rammensee,et al.  Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome‐dependent and ‐independent proteolytic activities , 1998, European journal of immunology.

[40]  W. Kast,et al.  Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Chesebro,et al.  Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors , 1996, Journal of virology.

[42]  M. Feltkamp,et al.  Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. , 1995, Journal of immunology.

[43]  J. Neefjes,et al.  The proteasome‐specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells , 1997, European journal of immunology.

[44]  A. Goldberg,et al.  γ-lnterferon and expression of MHC genes regulate peptide hydrolysis by proteasomes , 1995, Nature.

[45]  P M Kloetzel,et al.  Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes , 1994, The Journal of experimental medicine.

[46]  Günter J. Hämmerling,et al.  Selectivity of MHC-encoded peptide transporters from human, mouse and rat , 1994, Nature.

[47]  T. Elliott,et al.  Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum , 1995, The Journal of experimental medicine.

[48]  J. Yewdell,et al.  Trimming of antigenic peptides in an early secretory compartment , 1994, The Journal of experimental medicine.

[49]  P. Kloetzel,et al.  LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12 , 1996, The Journal of experimental medicine.

[50]  K Eichmann,et al.  Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. , 1995, Immunity.